The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples